BEGIN:VCALENDAR
PRODID:-//Columba Systems Ltd//NONSGML CPNG/SpringViewer/ICal Output/3.3-
 M3//EN
VERSION:2.0
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
DTSTAMP:20250730T092212Z
DTSTART:20250915T130000Z
DTEND:20250915T140000Z
SUMMARY:MBC Seminar – Prof Roger Gomis\, IRB Barcelona “ER+ Breast cancer
  metastasis cell fate mapping”
UID:{http://www.columbasystems.com/customers/uom/gpp/eventid/}edj-mdprbqw
 x-km3o58
DESCRIPTION:MBC Seminar – Prof Roger Gomis\, IRB Barcelona\n“ER+ Breast c
 ancer metastasis cell fate mapping”\n\nDate: Monday 15th September 2025\
 nTime: 14:00 – 15:00 \nVenue: Oglesby Cancer Research Building Lecture T
 heatre\, 555 Wilmslow Rd\, Manchester M20 4GJ \nHost: Rob Clarke\n\nNo s
 ign up needed\, just turn up on the day!\n\nProf Roger R Gomis is an ICR
 EA Research Professor and a member of the Cancer Science Program at the 
 Institute for Research in Biomedicine\, Barcelona. He received his PhD i
 n biochemistry from the University of Barcelona in 2002\, and was a post
 doctoral fellow at Memorial Sloan-Kettering Cancer Center in Prof. Joan 
 Massagué's laboratory. In 2007\, he assumed his current position. Since 
 2018 he is an associate professor at the University of Barcelona. \nThe 
 Gomis laboratory seeks to improve the prognosis\, prevention\, and treat
 ment of cancer by studying the basic principles underlying the developme
 nt of this disease. The lab has focused on identifying and functionally 
 validating genes that enable breast and colon cancers to metastasize to 
 clinically relevant sites. In particular\, during the last years\, the l
 ab strived to unravel the tissue-specific mediators and time dependent c
 omponents of metastasis processes. The goal is to improve metastasis tre
 atment\, with focus in prevention of dissemination. The lab findings hav
 e become an objective approach to selection of breast cancer patients fo
 r adjuvant bisphosphonates treatment to prevent metastasis (Coleman et a
 l. Lancet Oncol. 2017 and Paterson et al JNCICs 2021\, www.inbiomotion.c
 om [inbiomotion.com]). In addition\, the lab has provided insights into 
 how breast cancer metastatic epithelial cells remain latent\, by control
 ling luminal differentiation attributes through epigenetic marks\, which
  limits their initiation and expansion at the metastatic site (Gawrzak e
 t al Nat. Cell Biol. 2018) and how they are licensed for metastasis (Llo
 rente\, Blasco et al Nat. Cell. Biol. 2023).\n
STATUS:TENTATIVE
TRANSP:TRANSPARENT
CLASS:PUBLIC
LOCATION:Oglesby Cancer Research Building\, 555 Wilmslow Rd\, Manchester\
 , M20 4GJ
END:VEVENT
END:VCALENDAR